Aspen Neuroscience, Inc. has recently filed a Form 3 with the SEC, revealing significant details about its ownership structure. This filing is crucial as it provides transparency regarding the company's stakeholders and their respective holdings. Such updates are essential for investors and analysts who track the movements within the pharmaceutical preparations sector.
About Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. is a company focused on developing innovative therapies in the pharmaceutical preparations industry. The company is registered under the Central Index Key (CIK) 0002124080 and trades under the ticker symbol ASPE. The firm is incorporated in Delaware and has its business operations based in San Diego, California.
What the Filing Says
The filing, dated October 29, 2026, reveals that Peter A. Thompson is a ten-percent owner and a director of Aspen Neuroscience. The document indicates that Thompson holds various classes of convertible preferred stock, including:
- Series Seed-2 Convertible Preferred Stock: 196,541 shares
- Series A-1 Convertible Preferred Stock: 642,745 shares
- Series A-2 Convertible Preferred Stock: 616,984 shares
- Series B Convertible Preferred Stock: 625,743 shares
- Series C Convertible Preferred Stock: 507,119 shares
Each of these preferred shares can be converted into common stock at a specified ratio, which is significant for understanding the potential dilution of shares as the company grows.
Impact
This update may affect various stakeholders, including current and potential investors, as well as competitors in the pharmaceutical preparations sector. The transparency provided by this filing could influence investor confidence and market perceptions of Aspen Neuroscience. Additionally, it may prompt other companies in the industry to enhance their disclosure practices to maintain competitiveness.
What's Next
The filing does not specify what happens next for Aspen Neuroscience, but it sets the stage for future disclosures and potential strategic moves as the company continues to grow.
Read Next
Aspen Neuroscience reports key ownership changes post-IPO
Aspen Neuroscience reports key ownership changes in filing
Aspen Neuroscience reports ownership changes in SEC filing
Aspen Neuroscience reports ownership changes by director
Hobson Gillian A. Files Form 144 to Sell Shares in Group 1
TSPV P.G. Trust to Sell 35,000 Shares of Hyatt Hotels







